DBV Technologies S.A. — Form 8-K Summary
Reporting context: Current report dated September 29, 2026, reporting an event under Item 8.01. This is not a periodic financial report and provides no financial reporting period.
Business context and event
DBV Technologies announced submission of a Biologics License Application to the U.S. FDA for the VIASKIN Peanut Patch for children aged 4–7 years. The 8-K says the related press release is Exhibit 99.1 and incorporates it by reference, but the press release text is not included in the supplied filing content.
Financial information
The filing provides no revenue, profit, cash flow, margin, debt, liquidity, or other financial metrics.
Outlook, risks, and unusual items
No guidance, financial outlook, risk discussion, contingencies, or financial unusual items are provided in the supplied text. The reported event is the BLA submission; the filing does not provide submission details or FDA review timing.
Key facts to verify
- Review Exhibit 99.1 for the company’s full announcement and any additional details about the BLA submission.
- Verify the scope and timing of the FDA application and any subsequent regulatory updates.